Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 15/20 | 0.67 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | CCR1 | P32246 | 1/20 | 0.53 |
| ▸ | CCR5 | P51681 | 1/20 | 0.53 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4704983 | 1.00 | CCR2 (0.67) | CCR2GAACCR1CCR5CXCR4 | |
| SCHEMBL2462379 | 1.00 | CCR2 (0.67) | CCR2GAACCR1CCR5CXCR4 | |
| Acetic Acid SCHEMBL8778037 | 0.96 | CCR2 (0.62) | CCR2GAACCR1CCR5CXCR4 | |
| SCHEMBL29418355 | 0.95 | CCR2 (0.60) | CCR2GAACCR1CCR5CXCR4 | |
| SCHEMBL2462209 | 0.95 | CCR2 (0.60) | CCR2GAACCR1CCR5CXCR4 | |
| SCHEMBL203904 | 0.95 | CCR2 (0.60) | CCR2GAACCR1CCR5CXCR4 | |
| SCHEMBL203905 | 0.95 | CCR2 (0.60) | CCR2GAACCR1CCR5CXCR4 | |
| SCHEMBL2460843 | 0.95 | CCR2 (0.60) | CCR2GAACCR1CCR5CXCR4 | |
| SCHEMBL7322614 | 0.95 | CCR2 (0.60) | CCR2GAACCR1CCR5CXCR4 | |
| SCHEMBL7322622 | 0.95 | CCR2 (0.60) | CCR2GAACCR1CCR5CXCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-61134375-A | — | — | None | — | — | JP | disclosed |
| JP-61137850-A | — | — | None | — | — | JP | disclosed |
| US-20240317705-A1 | POTASSIUM CHANNEL MODULATORS | NOVARTIS AG (CH) | 2024-09-26 | — | — | US | disclosed |
| CN-115461049-A | (S) -2-amino-6- ((3-aminopropyl) amino) hexanoic Acid (APL) for the treatment of non-alcoholic steatohepatitis (NASH), liver inflammation, hepatocellular ballooning, liver fibrosis and steatosis | 坦普尔大学 | 2022-12-09 | — | — | CN | disclosed |
| US-10774064-B2 | Potassium channel modulators | CADENT THERAPEUTICS, INC. (US) | 2020-09-15 | — | — | US | disclosed |
| US-20190218200-A1 | POTASSIUM CHANNEL MODULATORS | NOVARTIS AG (CH) | 2019-07-18 | — | — | US | disclosed |
| US-9346852-B2 | Substituted adipic acid amides and uses thereof | BRISTOL-MYERS SCUIBB COMPANY (US) | 2016-05-24 | — | — | US | disclosed |
| US-20130345123-A1 | SUBSTITUTED ADIPIC ACID AMIDES AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-12-26 | — | — | US | disclosed |
| WO-2012125622-A1 | SUBSTITUTED ADIPIC ACID AMIDES AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-09-20 | — | — | WO | disclosed |
| US-8026233-B2 | P38 inhibitors and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2011-09-27 | — | — | US | disclosed |
| WO-1996040679-A1 | SUBSTITUTED (SULFINIC ACID, SULFONIC ACID, SULFONYLAMINO OR SULFINYLAMINO) N-[(AMINOIMINOMETHYL)PHENYLALKYL]-AZAHETEROCYCLYLAMIDE COMPOUNDS | RHÔNE-POULENC RORER PHARMACEUTICALS INC. (US) | 1996-12-19 | — | — | WO | disclosed |
| US-5552397-A | HYPOTENSIVE AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1996-09-03 | — | — | US | disclosed |
| EP-0599444-A1 | Dual action inhibitors | E.R. SQUIBB & SONS, INC. (US) | 1994-06-01 | — | — | EP | disclosed |
| US-4598071-A | ANGIOTENSIN INHIBITORS/ | E. R. SQUIBB & SONS, INC. (US) | 1986-07-01 | — | — | US | disclosed |
| JP-S61137850-A | PRODUCTION OF D-OR L-N2-T-BUTOXYCARBONYLLYSINE | TORAY IND INC | 1986-06-25 | — | — | JP | disclosed |
| JP-S61134375-A | L-OR D-ALPHA-T-BUTOXYCARBONYLAMINO-EPSILON-CAPROLACTAM | TORAY IND INC | 1986-06-21 | — | — | JP | disclosed |
| US-4567167-A | INHIBITOR OF ANGIOTENDIN CONVERTING ENZYME | E. R. SQUIBB & SONS, INC. (US) | 1986-01-28 | — | — | US | disclosed |
| US-4533661-A | Certain 3-phosphinyl-amino-2-oxo-1H-azepine-1-acetic acid derivatives having anti-hypertensive activity | E. R. SQUIBB & SONS, INC. (US) | 1985-08-06 | — | — | US | disclosed |
| EP-0142335-A2 | Lactam containing compounds | E.R. Squibb & Sons, Inc. (US) | 1985-05-22 | — | — | EP | disclosed |
| US-4474778-A | HYPOTENSIVE AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1984-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240317705-A1 | POTASSIUM CHANNEL MODULATORS | KCNJ11, KCNJ2, KCNJ1 | CCR2 4758/4885GAA 1172/4885CCR1 4739/4885 |
| US-10774064-B2 | Potassium channel modulators | KCNJ11, KCNJ2, KCNJ1 | CCR2 4758/4885GAA 1172/4885CCR1 4739/4885 |
| US-20190218200-A1 | POTASSIUM CHANNEL MODULATORS | KCNJ11, KCNJ2, KCNJ1 | CCR2 4758/4885GAA 1172/4885CCR1 4739/4885 |
| US-20130345123-A1 | SUBSTITUTED ADIPIC ACID AMIDES AND USES THEREOF | NPY4R, ADIPOR1, NPY1R | CCR2 321/4885GAA 3387/4885CCR1 482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.